Share Price and Basic Stock Data
Last Updated: December 24, 2025, 9:10 pm
| PEG Ratio | 2.40 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Insecticides India Ltd operates in the agrochemicals and pesticides sector, demonstrating a resilient revenue trajectory. For the fiscal year ending March 2025, the company reported sales of ₹2,002 Cr, a significant increase from ₹1,966 Cr in March 2024. Analyzing quarterly sales, the latest figures show a rise from ₹640 Cr in June 2023 to ₹691 Cr in June 2025. This upward trend highlights the company’s ability to adapt to market demands and potentially capitalize on the growing agricultural sector in India. The increase in sales reflects a strong market position, supported by a diverse product portfolio. However, the company experienced fluctuations throughout the year, with a notable dip to ₹302 Cr in March 2023, indicating potential seasonal impacts or market challenges. Overall, the reported sales figures suggest a robust recovery and growth potential, aligning with the industry’s demand for effective agricultural solutions.
Profitability and Efficiency Metrics
Insecticides India Ltd reported a net profit of ₹140 Cr for the fiscal year ending March 2025, up from ₹103 Cr in March 2024, indicating a positive trend in profitability. The operating profit margin (OPM) stood at 11% in March 2025, reflecting a recovery from the low of 7% in March 2023. With an interest coverage ratio of 33.25x, the company demonstrates strong ability to meet its interest obligations, suggesting robust operational efficiency. However, the OPM fluctuated during the fiscal year, with a low of 3% in March 2024, indicating potential cost pressures. The return on equity (ROE) was recorded at 13.3%, which is competitive in the agrochemical sector, suggesting effective utilization of shareholder funds. The operational efficiency metrics indicate that while the company is moving towards improved profitability, it must remain vigilant about managing expenses to sustain these margins in a competitive market landscape.
Balance Sheet Strength and Financial Ratios
The balance sheet of Insecticides India Ltd reveals a sound financial position with total assets reported at ₹1,888 Cr as of March 2025. The company maintains healthy reserves of ₹1,167 Cr, providing a buffer for operational activities and expansion plans. Borrowings stood at ₹242 Cr, reflecting a manageable debt level with a total debt-to-equity ratio of 0.09, indicating low leverage compared to industry standards. The current ratio of 1.83 suggests that the company possesses sufficient liquidity to cover short-term liabilities. Additionally, the interest coverage ratio of 33.25x reinforces its ability to meet interest obligations comfortably. However, the cash conversion cycle (CCC) of 185 days indicates areas for improvement in working capital management. Overall, the balance sheet metrics demonstrate stability, but the company should focus on optimizing working capital to enhance operational efficiency further.
Shareholding Pattern and Investor Confidence
The shareholding structure of Insecticides India Ltd illustrates a stable promoter holding of 72.30% as of March 2025, which is a positive indicator of management confidence in the company’s prospects. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold 4.51% and 9.50% of shares, respectively, reflecting a moderate level of institutional interest. The public shareholding stands at 13.69%, indicating a healthy distribution among retail investors. Over the past year, the number of shareholders increased to 22,336, suggesting growing investor interest. The consistent promoter stake, combined with rising retail participation, enhances investor confidence. However, the decline in FII participation from 6.27% in December 2022 to 4.51% in March 2025 may raise concerns about international market perceptions. Overall, the shareholding pattern reflects a stable foundation for future growth, albeit with some caution regarding institutional sentiment.
Outlook, Risks, and Final Insight
The outlook for Insecticides India Ltd appears cautiously optimistic, driven by strong revenue growth and improving profitability metrics. The company’s ability to navigate market fluctuations and maintain operational efficiency will be critical for sustaining this momentum. However, risks such as fluctuating raw material costs, regulatory changes, and increasing competition in the agrochemical sector could impact margins and profitability. Additionally, the high cash conversion cycle indicates potential inefficiencies in managing working capital that could affect liquidity. If the company successfully addresses these challenges while leveraging its established market position, it could enhance shareholder value and sustain growth. Conversely, failure to adapt to market dynamics could hinder progress. In conclusion, while Insecticides India Ltd shows promise, it must remain vigilant of external challenges to capitalize on its growth potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 5,688 Cr. | 1,319 | 2,114/1,315 | 14.2 | 487 | 0.45 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 810 Cr. | 240 | 391/165 | 16.6 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 67.3 Cr. | 129 | 149/56.6 | 12.1 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,934 Cr. | 227 | 331/222 | 111 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 914 Cr. | 387 | 645/244 | 71.4 | 342 | 0.77 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,050.00 Cr | 1,141.50 | 32.24 | 382.34 | 0.43% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 561 | 582 | 357 | 302 | 640 | 696 | 358 | 272 | 657 | 627 | 359 | 359 | 691 |
| Expenses | 502 | 514 | 333 | 330 | 594 | 614 | 332 | 263 | 585 | 537 | 331 | 331 | 607 |
| Operating Profit | 58 | 68 | 23 | -28 | 46 | 82 | 26 | 9 | 72 | 90 | 29 | 28 | 84 |
| OPM % | 10% | 12% | 7% | -9% | 7% | 12% | 7% | 3% | 11% | 14% | 8% | 8% | 12% |
| Other Income | 0 | 0 | 0 | 0 | 4 | -0 | 1 | 5 | 3 | 2 | 0 | 3 | 4 |
| Interest | 1 | 3 | 5 | 4 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 4 |
| Depreciation | 7 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 7 | 7 | 8 | 7 | 7 |
| Profit before tax | 51 | 60 | 12 | -39 | 39 | 72 | 17 | 4 | 66 | 82 | 20 | 22 | 77 |
| Tax % | 25% | 25% | 25% | -26% | 26% | 26% | 28% | -95% | 25% | 25% | 25% | 37% | 25% |
| Net Profit | 38 | 45 | 9 | -29 | 29 | 53 | 12 | 8 | 49 | 62 | 15 | 14 | 57 |
| EPS in Rs | 12.84 | 15.09 | 3.15 | -9.80 | 9.81 | 17.99 | 4.15 | 2.73 | 16.60 | 20.81 | 5.07 | 4.74 | 19.36 |
Last Updated: August 20, 2025, 9:00 am
Below is a detailed analysis of the quarterly data for Insecticides India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 691.00 Cr.. The value appears strong and on an upward trend. It has increased from 359.00 Cr. (Mar 2025) to 691.00 Cr., marking an increase of 332.00 Cr..
- For Expenses, as of Jun 2025, the value is 607.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 331.00 Cr. (Mar 2025) to 607.00 Cr., marking an increase of 276.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 56.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears strong and on an upward trend. It has increased from 8.00% (Mar 2025) to 12.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 55.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Mar 2025) to 25.00%, marking a decrease of 12.00%.
- For Net Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 43.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 19.36. The value appears strong and on an upward trend. It has increased from 4.74 (Mar 2025) to 19.36, marking an increase of 14.62.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 801 | 892 | 906 | 994 | 1,073 | 1,194 | 1,363 | 1,420 | 1,504 | 1,801 | 1,966 | 2,002 | 2,051 |
| Expenses | 719 | 781 | 815 | 880 | 925 | 1,006 | 1,207 | 1,268 | 1,333 | 1,679 | 1,803 | 1,783 | 1,825 |
| Operating Profit | 82 | 111 | 91 | 114 | 148 | 188 | 156 | 153 | 171 | 122 | 163 | 219 | 226 |
| OPM % | 10% | 12% | 10% | 11% | 14% | 16% | 11% | 11% | 11% | 7% | 8% | 11% | 11% |
| Other Income | 0 | 0 | 0 | 4 | 3 | 0 | 2 | -2 | 3 | 1 | 10 | 7 | 10 |
| Interest | 27 | 33 | 26 | 20 | 16 | 15 | 24 | 7 | 7 | 13 | 11 | 7 | 11 |
| Depreciation | 7 | 14 | 16 | 16 | 17 | 20 | 24 | 25 | 26 | 26 | 29 | 29 | 31 |
| Profit before tax | 49 | 64 | 50 | 82 | 118 | 153 | 110 | 119 | 141 | 84 | 133 | 190 | 193 |
| Tax % | 18% | 15% | 21% | 28% | 29% | 20% | 22% | 22% | 24% | 25% | 23% | 27% | |
| Net Profit | 40 | 55 | 39 | 59 | 84 | 122 | 86 | 93 | 107 | 63 | 103 | 140 | 142 |
| EPS in Rs | 14.01 | 19.24 | 12.67 | 19.16 | 27.09 | 39.49 | 27.75 | 30.14 | 36.16 | 21.28 | 34.67 | 48.03 | 48.68 |
| Dividend Payout % | 10% | 0% | 11% | 7% | 5% | 3% | 10% | 4% | 6% | 14% | 9% | 4% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.50% | -29.09% | 51.28% | 42.37% | 45.24% | -29.51% | 8.14% | 15.05% | -41.12% | 63.49% | 35.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | -66.59% | 80.37% | -8.91% | 2.87% | -74.75% | 37.65% | 6.91% | -56.18% | 104.61% | -27.57% |
Insecticides India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 10% |
| 3 Years: | 9% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 20% |
| 3 Years: | 8% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 7:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:26 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 30 | 30 | 29 | 29 |
| Reserves | 234 | 279 | 388 | 444 | 527 | 641 | 710 | 798 | 847 | 886 | 982 | 1,053 | 1,167 |
| Borrowings | 258 | 322 | 206 | 237 | 114 | 305 | 191 | 100 | 54 | 163 | 87 | 104 | 242 |
| Other Liabilities | 287 | 308 | 322 | 277 | 338 | 388 | 372 | 505 | 473 | 615 | 611 | 702 | 536 |
| Total Liabilities | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,888 | 1,973 |
| Fixed Assets | 170 | 205 | 194 | 185 | 232 | 240 | 239 | 239 | 253 | 262 | 283 | 278 | 380 |
| CWIP | 54 | 38 | 51 | 58 | 17 | 19 | 39 | 59 | 91 | 123 | 141 | 161 | 81 |
| Investments | 11 | 11 | 11 | 11 | 16 | 12 | 10 | 12 | 13 | 15 | 19 | 26 | 29 |
| Other Assets | 556 | 667 | 680 | 725 | 735 | 1,084 | 1,004 | 1,115 | 1,037 | 1,293 | 1,267 | 1,422 | 1,483 |
| Total Assets | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,888 | 1,973 |
Below is a detailed analysis of the balance sheet data for Insecticides India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,167.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,053.00 Cr. (Mar 2025) to 1,167.00 Cr., marking an increase of 114.00 Cr..
- For Borrowings, as of Sep 2025, the value is 242.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 104.00 Cr. (Mar 2025) to 242.00 Cr., marking an increase of 138.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 536.00 Cr.. The value appears to be improving (decreasing). It has decreased from 702.00 Cr. (Mar 2025) to 536.00 Cr., marking a decrease of 166.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,973.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,888.00 Cr. (Mar 2025) to 1,973.00 Cr., marking an increase of 85.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 380.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 380.00 Cr., marking an increase of 102.00 Cr..
- For CWIP, as of Sep 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 80.00 Cr..
- For Investments, as of Sep 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2025) to 29.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,483.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,422.00 Cr. (Mar 2025) to 1,483.00 Cr., marking an increase of 61.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,973.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,888.00 Cr. (Mar 2025) to 1,973.00 Cr., marking an increase of 85.00 Cr..
Notably, the Reserves (1,167.00 Cr.) exceed the Borrowings (242.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -176.00 | -211.00 | -115.00 | -123.00 | 34.00 | -117.00 | -35.00 | 53.00 | 117.00 | -41.00 | 76.00 | 115.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 68 | 84 | 78 | 80 | 75 | 86 | 65 | 70 | 60 | 55 | 70 |
| Inventory Days | 189 | 220 | 190 | 232 | 214 | 355 | 202 | 248 | 228 | 247 | 220 | 265 |
| Days Payable | 124 | 118 | 114 | 108 | 128 | 141 | 96 | 136 | 117 | 128 | 114 | 150 |
| Cash Conversion Cycle | 124 | 170 | 159 | 201 | 166 | 289 | 192 | 177 | 181 | 178 | 161 | 185 |
| Working Capital Days | 18 | 40 | 75 | 80 | 93 | 116 | 98 | 108 | 111 | 92 | 99 | 107 |
| ROCE % | 16% | 17% | 12% | 16% | 20% | 21% | 14% | 15% | 16% | 10% | 13% | 17% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 2,636,351 | 0.5 | 190.87 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 48.38 | 34.59 | 21.36 | 54.17 | 45.43 |
| Diluted EPS (Rs.) | 48.38 | 34.59 | 21.36 | 54.17 | 45.43 |
| Cash EPS (Rs.) | 58.63 | 44.36 | 30.10 | 67.59 | 57.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 372.74 | 342.44 | 310.26 | 440.71 | 396.93 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 372.74 | 342.44 | 310.26 | 440.71 | 396.93 |
| Revenue From Operations / Share (Rs.) | 687.32 | 664.37 | 608.60 | 762.20 | 687.17 |
| PBDIT / Share (Rs.) | 78.43 | 58.12 | 41.61 | 88.16 | 77.44 |
| PBIT / Share (Rs.) | 68.41 | 48.24 | 32.79 | 74.80 | 65.51 |
| PBT / Share (Rs.) | 66.05 | 44.56 | 28.24 | 71.44 | 57.59 |
| Net Profit / Share (Rs.) | 48.61 | 34.48 | 21.28 | 54.24 | 45.21 |
| NP After MI And SOA / Share (Rs.) | 48.81 | 34.59 | 21.36 | 54.44 | 45.43 |
| PBDIT Margin (%) | 11.41 | 8.74 | 6.83 | 11.56 | 11.26 |
| PBIT Margin (%) | 9.95 | 7.26 | 5.38 | 9.81 | 9.53 |
| PBT Margin (%) | 9.60 | 6.70 | 4.64 | 9.37 | 8.38 |
| Net Profit Margin (%) | 7.07 | 5.18 | 3.49 | 7.11 | 6.57 |
| NP After MI And SOA Margin (%) | 7.10 | 5.20 | 3.50 | 7.14 | 6.61 |
| Return on Networth / Equity (%) | 13.09 | 10.09 | 6.88 | 12.35 | 11.44 |
| Return on Capital Employeed (%) | 17.76 | 13.50 | 10.35 | 16.61 | 16.09 |
| Return On Assets (%) | 7.48 | 5.97 | 3.72 | 7.69 | 6.58 |
| Long Term Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.09 | 0.08 | 0.17 | 0.05 | 0.11 |
| Asset Turnover Ratio (%) | 1.11 | 1.15 | 1.16 | 1.07 | 1.04 |
| Current Ratio (X) | 1.83 | 1.90 | 1.62 | 1.97 | 1.86 |
| Quick Ratio (X) | 0.69 | 0.67 | 0.48 | 0.73 | 0.72 |
| Inventory Turnover Ratio (X) | 2.36 | 1.60 | 1.88 | 1.61 | 1.77 |
| Dividend Payout Ratio (NP) (%) | 4.16 | 8.67 | 23.41 | 0.00 | 4.40 |
| Dividend Payout Ratio (CP) (%) | 3.45 | 6.74 | 16.56 | 0.00 | 3.48 |
| Earning Retention Ratio (%) | 95.84 | 91.33 | 76.59 | 0.00 | 95.60 |
| Cash Earning Retention Ratio (%) | 96.55 | 93.26 | 83.44 | 0.00 | 96.52 |
| Interest Coverage Ratio (X) | 33.25 | 15.80 | 9.16 | 26.22 | 24.06 |
| Interest Coverage Ratio (Post Tax) (X) | 21.61 | 10.37 | 5.68 | 17.13 | 16.51 |
| Enterprise Value (Cr.) | 1764.96 | 1468.53 | 1522.18 | 1224.20 | 990.06 |
| EV / Net Operating Revenue (X) | 0.88 | 0.74 | 0.84 | 0.81 | 0.69 |
| EV / EBITDA (X) | 7.73 | 8.54 | 12.36 | 7.04 | 6.19 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 0.73 | 0.76 | 0.80 | 0.68 |
| Retention Ratios (%) | 95.83 | 91.32 | 76.58 | 0.00 | 95.59 |
| Price / BV (X) | 1.59 | 1.43 | 1.51 | 1.39 | 1.19 |
| Price / Net Operating Revenue (X) | 0.86 | 0.73 | 0.76 | 0.80 | 0.68 |
| EarningsYield | 0.08 | 0.07 | 0.04 | 0.08 | 0.09 |
After reviewing the key financial ratios for Insecticides India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 48.38. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.38, marking an increase of 13.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 58.63. This value is within the healthy range. It has increased from 44.36 (Mar 24) to 58.63, marking an increase of 14.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 372.74. It has increased from 342.44 (Mar 24) to 372.74, marking an increase of 30.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 687.32. It has increased from 664.37 (Mar 24) to 687.32, marking an increase of 22.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 78.43. This value is within the healthy range. It has increased from 58.12 (Mar 24) to 78.43, marking an increase of 20.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 68.41. This value is within the healthy range. It has increased from 48.24 (Mar 24) to 68.41, marking an increase of 20.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 66.05. This value is within the healthy range. It has increased from 44.56 (Mar 24) to 66.05, marking an increase of 21.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 48.61. This value is within the healthy range. It has increased from 34.48 (Mar 24) to 48.61, marking an increase of 14.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.81. This value is within the healthy range. It has increased from 34.59 (Mar 24) to 48.81, marking an increase of 14.22.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 8.74 (Mar 24) to 11.41, marking an increase of 2.67.
- For PBIT Margin (%), as of Mar 25, the value is 9.95. This value is below the healthy minimum of 10. It has increased from 7.26 (Mar 24) to 9.95, marking an increase of 2.69.
- For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 6.70 (Mar 24) to 9.60, marking an increase of 2.90.
- For Net Profit Margin (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has increased from 5.18 (Mar 24) to 7.07, marking an increase of 1.89.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.10. This value is below the healthy minimum of 8. It has increased from 5.20 (Mar 24) to 7.10, marking an increase of 1.90.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.09. This value is below the healthy minimum of 15. It has increased from 10.09 (Mar 24) to 13.09, marking an increase of 3.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.76. This value is within the healthy range. It has increased from 13.50 (Mar 24) to 17.76, marking an increase of 4.26.
- For Return On Assets (%), as of Mar 25, the value is 7.48. This value is within the healthy range. It has increased from 5.97 (Mar 24) to 7.48, marking an increase of 1.51.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has decreased from 1.15 (Mar 24) to 1.11, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.83, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.69, marking an increase of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 4. It has increased from 1.60 (Mar 24) to 2.36, marking an increase of 0.76.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.16. This value is below the healthy minimum of 20. It has decreased from 8.67 (Mar 24) to 4.16, marking a decrease of 4.51.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 20. It has decreased from 6.74 (Mar 24) to 3.45, marking a decrease of 3.29.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.84. This value exceeds the healthy maximum of 70. It has increased from 91.33 (Mar 24) to 95.84, marking an increase of 4.51.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.55. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 96.55, marking an increase of 3.29.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 33.25. This value is within the healthy range. It has increased from 15.80 (Mar 24) to 33.25, marking an increase of 17.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.61. This value is within the healthy range. It has increased from 10.37 (Mar 24) to 21.61, marking an increase of 11.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,764.96. It has increased from 1,468.53 (Mar 24) to 1,764.96, marking an increase of 296.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has increased from 0.74 (Mar 24) to 0.88, marking an increase of 0.14.
- For EV / EBITDA (X), as of Mar 25, the value is 7.73. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 7.73, marking a decrease of 0.81.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
- For Retention Ratios (%), as of Mar 25, the value is 95.83. This value exceeds the healthy maximum of 70. It has increased from 91.32 (Mar 24) to 95.83, marking an increase of 4.51.
- For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 1.59, marking an increase of 0.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has increased from 0.73 (Mar 24) to 0.86, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.08, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Insecticides India Ltd:
- Net Profit Margin: 7.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.76% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.09% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 21.61
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.7 (Industry average Stock P/E: 32.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | 401-402, Lusa Tower, Delhi Delhi 110033 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hari Chand Aggarwal | Chairman & Wholetime Director |
| Mr. Rajesh Kumar Aggarwal | Managing Director |
| Mr. Nikunj Aggarwal | Whole Time Director |
| Mr. Anil Kumar Goyal | Whole Time Director |
| Ms. Praveen Gupta | Independent Director |
| Mr. Anil Kumar Bhatia | Independent Director |
| Mr. Shyam Lal Bansal | Independent Director |
| Mr. Supratim Bandyopadhay | Independent Director |
FAQ
What is the intrinsic value of Insecticides India Ltd?
Insecticides India Ltd's intrinsic value (as of 24 December 2025) is 644.64 which is 9.84% lower the current market price of 715.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,088 Cr. market cap, FY2025-2026 high/low of 1,098/532, reserves of ₹1,167 Cr, and liabilities of 1,973 Cr.
What is the Market Cap of Insecticides India Ltd?
The Market Cap of Insecticides India Ltd is 2,088 Cr..
What is the current Stock Price of Insecticides India Ltd as on 24 December 2025?
The current stock price of Insecticides India Ltd as on 24 December 2025 is 715.
What is the High / Low of Insecticides India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Insecticides India Ltd stocks is 1,098/532.
What is the Stock P/E of Insecticides India Ltd?
The Stock P/E of Insecticides India Ltd is 14.7.
What is the Book Value of Insecticides India Ltd?
The Book Value of Insecticides India Ltd is 411.
What is the Dividend Yield of Insecticides India Ltd?
The Dividend Yield of Insecticides India Ltd is 0.28 %.
What is the ROCE of Insecticides India Ltd?
The ROCE of Insecticides India Ltd is 17.2 %.
What is the ROE of Insecticides India Ltd?
The ROE of Insecticides India Ltd is 13.3 %.
What is the Face Value of Insecticides India Ltd?
The Face Value of Insecticides India Ltd is 10.0.